Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07522099
PHASE2

Chinese Adults With Kidney Disease

Sponsor: ADARx Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Official title: A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-07-23

Completion Date

2029-01-21

Last Updated

2026-05-01

Healthy Volunteers

No

Interventions

DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Telitacicept

fusion protein

Locations (10)

ADARx Clinical Site

Shenzhen, Guangdong, China

ADARx Clinical Site

Guiyang, Guizhou, China

ADARx Clinical Site

Zhengzhou, Henan, China

ADARx Clinical Site

Baotou, Inner Mongolia, China

ADARx Clinical Site

Wuxi, Jiangsu, China

ADARx Clinical Site

Yantai, Shandong, China

ADARx Clinical Site

Beijing, China

ADARx Clinical Site

Shandong, China

ADARx Clinical Site

Shanghai, China

ADARx Clinical Site

Shangxi, China